Maraslavin® (Solution) Instructions for Use
Marketing Authorization Holder
Sopharma, JSC (Bulgaria)
ATC Code
A01AD11 (Other drugs)
Dosage Form
| Maraslavin® | Solution for topical use: bottle 100 ml |
Dosage Form, Packaging, and Composition
Solution for topical use is turbid, of red-brown color, with an astringent-sour taste, and a specific odor; sediment may form during storage.
| 100 ml | |
| Artemisia pontica herb | 4.196 g |
| Satureja hortensis herb | 728 mg |
| Clove flowers | 3.646 g |
| Black pepper fruit | 1.199 g |
| Zingiber officinale rhizome | 4.196 g |
Excipients: ammonium chloride, wine vinegar, water.
100 ml – dark glass bottles (1) – cardboard boxes.
Clinical-Pharmacological Group
Drug used for periodontal diseases and gingivitis
Pharmacotherapeutic Group
Antiseptic of plant origin
Pharmacological Action
Maraslavin® is a combined herbal preparation for topical use in dentistry. It has antimicrobial, anti-inflammatory, anti-allergic, astringent, local irritant, and analgesic effects, and improves tissue regeneration.
At the beginning of the treatment course, the application of the drug causes irritation, hyperemia, and swelling of the gum mucosa. The hypertonic solution of Maraslavin® helps to remove toxic decay products from the gingival pockets.
Then, an increase in the number of collagen fibers is observed, the gum tissues become denser, new epithelium is formed, the normal structure of the gums is restored, and the connection of the periodontium with the cementum of the tooth root is strengthened.
In the treatment of the hemorrhagic form of periodontosis, a reduction in gum swelling and bleeding first occurs, the color of the gums becomes pale, and then pale pink, the structure of the gums becomes denser, the gingival papillae thin out and gradually press against the neck of the tooth at the subenamel-cement border. Gingival pockets decrease or disappear.
In the purulent form of periodontosis, an increase in the amount of purulent exudate is observed in the first days, then its amount gradually decreases until it completely disappears. The gingival papillae are resorbed, the edges of the gums are leveled and tightly pressed against the teeth. Stabilization of tooth mobility occurs.
Pharmacokinetics
Data on the pharmacokinetics of Maraslavin® are not available.
Indications
- Hemorrhagic form of periodontosis with alveolar pockets;
- Purulent form of periodontosis (as part of complex therapy);
- Postoperative period after surgical treatment of periodontosis.
ICD codes
| ICD-10 code | Indication |
| K05 | Gingivitis and periodontal diseases |
| ICD-11 code | Indication |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Treatment with Maraslavin® is carried out by a dentist and begins with the removal of supragingival dental calculus. Simultaneously, ventilation of the gingival pockets is performed with a spray or a stream of warm water.
Then, loose cotton tampons, abundantly moistened with Maraslavin®, are inserted into the gingival and bone pockets using a probe. For this, 20-25 ml of the preparation is poured into a glass vessel, with which cotton tampons are abundantly moistened; the size of the tampons depends on the width of the alveolar or bone pocket.
The tampons are left in the pockets for 5-6 minutes. This procedure is repeated 5-6 times during the first session, sequentially on each pocket. With each change of the tampon, it penetrates easier and deeper into the alveolar pocket. The last time, the tampons are left loosely lying in the pockets until the next session. The patient is warned that in case of a rise in temperature (due to purulent exudation), they can remove the tampons themselves and consult a dentist.
At the second session, the tampons remaining from the first session are removed and subgingival dental calculus is removed. Tampons are inserted into the pocket several times, as in the first session. The last time, the tampons are also left in the pockets until the next session.
Treatment is carried out at intervals over 3 months. 17-20 treatment sessions should be conducted. The first 5-6 sessions should be conducted at 24-hour intervals. Subsequent treatment courses are prescribed by the dentist.
A control examination of the patient is carried out 5-6 months after the start of treatment. Regardless of the condition of the gums, the same areas on the alveoli are treated with Maraslavin® 1-2 times (more if necessary) to eliminate possible pathogens. A final examination is carried out 12 months after the start of treatment.
Adverse Reactions
Possible allergic reactions.
With tight packing of the tampons, subfebrile temperature is possible, due to impaired outflow of purulent exudate, which disappears on its own after the removal of the tampons.
Contraindications
- Hypersensitivity to the components of the drug.
Use in Pregnancy and Lactation
Data on the use of the drug during pregnancy and lactation are not available.
Special Precautions
The patient is recommended to take food rich in vitamins and additional intake of vitamins A and C.
During the treatment period, spicy and irritating foods (garlic, onions, nuts) should not be consumed.
During therapy with Maraslavin®, one should not brush teeth with a toothbrush and toothpaste or use disinfectant liquids for mouth rinsing. The oral cavity should be rinsed with cool water in the morning and evening.
Prolonged exposure to the sun should be avoided.
Overdose
Cases of overdose with Maraslavin® have not been observed to date.
Drug Interactions
Drug interactions of Maraslavin® have not been established.
Storage Conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25°C (77°F).
Shelf Life
Shelf life – 3 years.
Dispensing Status
The drug is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Daivobet, ointment, 30g
Arbidol, capsules 100mg, 40pcs
Mildronate capsules 500mg, 90pcs
Phenibut-Vertex pills 250mg, 20pcs
OKI, sachets 80mg 2g, 12pcs
Picamilon pills 50mg, 60pcs
Fenotropil pills 100mg, 60pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Kagocel pills 12mg, 30pcs
Actovegin pills 200mg, 50pcs
Cortexin, 10mg, 5ml, 10pcs
Ingavirin capsules 90mg, 10pcs
Belosalic, ointment, 30g
Nootropil pills 800mg, 30pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Belosalic, lotion solution for external use spray 100ml
No-spa pills 40mg, 64pcs
Noopept, pills 10mg, 50pcs 